JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 56(2022) N 1 p. 107-114; DOI 10.1134/S0026893322010083 Full Text

F.A. Urusov1,2*, D.V. Glazkova1, G.M. Tsyganova1, D.V. Pozdyshev3, E.V. Bogoslovskaya1, G.A. Shipulin1

The Titer of the Lentiviral Vector Encoding Chimeric TRIM5α-HRH Gene is Reduced Due to Expression of TRIM5α-HRH in Producer Cells and the Negative Effect of Efla Promoter

1Center for Strategic Planning and Management of Medical and Biological Health Risks, Federal Medical-Biological Agency of the Russian Federation, Moscow, 119992 Russia
2Izmerov Research Institute of Occupational Health, Moscow, 105275 Russia
3Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, 119992 Russia

*flanger.fx@mail.ru
Received - 2021-04-02; Revised - 2021-06-11; Accepted - 2021-06-11

The chimeric protein TRIM5α-HRH is a promising antiviral factor for HIV-1 gene therapy. This protein is able to protect cells from HIV-1 by blocking the virus in the cytoplasm. We are developing protocol of HIV-1 gene therapy, which involves the delivery of the TRIM5α-HRH gene into CD4+ T-lymphocytes by lentiviral vectors (LVs). However, LVs containing TRIM5α-HRH have a low infectious titer, which prevents effective T cell modification. Here, we found that the expression of TRIM5α-HRH during pseudoviral particle production in HEK293 T cells, as well as the presence of the Eflα promoter in our construction are responsible for titer reduction. These results allow us to determine the directions for further optimization of LV with the TRIM5α-HRH gene to improve its infectious titer.

TRIM5α, TRIM5α-HRH, gene therapy, HIV-1, Eflα, lentiviral vector



JMB-FOOTER RAS-JOURNALS